

Investigating the effect of bintrafusp alfa, a bifunctional fusion protein designed for colocalized, simultaneous inhibition of the TGF- β and PD-L1 pathways, in multiple cancer types.

Bintrafusp alfa is under clinical investigation and has not been proven to be safe and effective. There is no guarantee that bintrafusp alfa will be approved in the sought-after indication by any health authority worldwide.

INTR@PID[™] BTC 055¹

Now Enrolling



LOCALLY ADVANCED/METASTATIC
BTC




PHASE 2/3
RANDOMIZED



COMBINATION
THERAPY

INTR@PID BTC 055 (NCT04066491) is a safety run-in followed by a phase 2/3, randomized, placebo-controlled study evaluating bintrafusp alfa with gemcitabine plus cisplatin in the first-line treatment of patients with locally advanced or metastatic biliary tract cancer (BTC).

Study design | Global



Key inclusion criteria[†]

- Participants must have histologically or cytologically confirmed locally advanced or metastatic BTC, be naive to chemotherapy and immunotherapy, and have an ECOG PS of 0 or 1


Key exclusion criteria[†]

- Participants must not have a history of or concurrent interstitial lung disease

*Until confirmed disease progression, death, unacceptable toxicity, study withdrawal, or 2 years after the first onset of complete response. [†]For a full list of inclusion and exclusion criteria, please visit www.clinicaltrials.gov.

1L, first line; BTC, biliary tract cancer; DLT, dose-limiting toxicity; DOR, duration of response; DRR, durable response rate; ECOG PS, Eastern Cooperative Oncology Group performance status; IV, intravenous; OR, objective response; OS, overall survival; PD-L1, programmed death ligand 1; PFS, progression-free survival; Q3W, every 3 weeks; R, randomized; TGF- β , transforming growth factor β .

Reference: 1. ClinicalTrials.gov. Gemcitabine plus cisplatin with or without bintrafusp alfa (M7824) in participants with 1L biliary tract cancer (BTC). Accessed March 11, 2021. <https://clinicaltrials.gov/ct2/show/NCT04066491>.



Are your patients eligible?



For more information, visit
www.intrapidclinicaltrials.com
www.clinicaltrials.gov